Oncogenesis (Oct 2022)

A MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancer

  • Mijeong Kim,
  • Manjot Singh,
  • Bum-Kyu Lee,
  • Moira Hibbs,
  • Kirsty Richardson,
  • Lesley Ellies,
  • Larissa Wintle,
  • Lisa M. Stuart,
  • Jenny Y. Wang,
  • Dominic C. Voon,
  • Pilar Blancafort,
  • Jianlong Wang,
  • Jonghwan Kim,
  • Peter J. Leedman,
  • Andrew J. Woo

DOI
https://doi.org/10.1038/s41389-022-00435-1
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 13

Abstract

Read online

Abstract The MYC proto-oncogene (MYC) is one of the most frequently overexpressed genes in breast cancer that drives cancer stem cell-like traits, resulting in aggressive disease progression and poor prognosis. In this study, we identified zinc finger transcription factor 148 (ZNF148, also called Zfp148 and ZBP-89) as a direct target of MYC. ZNF148 suppressed cell proliferation and migration and was transcriptionally repressed by MYC in breast cancer. Depletion of ZNF148 by short hairpin RNA (shRNA) and CRISPR/Cas9 increased triple-negative breast cancer (TNBC) cell proliferation and migration. Global transcriptome and chromatin occupancy analyses of ZNF148 revealed a central role in inhibiting cancer cell de-differentiation and migration. Mechanistically, we identified the Inhibitor of DNA binding 1 and 3 (ID1, ID3), drivers of cancer stemness and plasticity, as previously uncharacterized targets of transcriptional repression by ZNF148. Silencing of ZNF148 increased the stemness and tumorigenicity in TNBC cells. These findings uncover a previously unknown tumor suppressor role for ZNF148, and a transcriptional regulatory circuitry encompassing MYC, ZNF148, and ID1/3 in driving cancer stem cell traits in aggressive breast cancer.